ReviewKorean circulation journal2020
Percutaneous Pulmonary Valve Implantation.
Review in Korean circulation journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Mechanical-medical convergence in heart failure: Artificial intelligence, finite-element modeling, and 3D printing for diagnosis and prognosis.Bioengineering & translational medicine · 2026Review
- 3D Modeling of Self-Expandable Valves for PPVI in Distinct RVOT Morphologies.Pediatric cardiology · 2026Article
- First Transcatheter Pulmonary Valve Replacement in Tanzania: Feasibility of Advanced Cardiac Interventions in Resource-Limited Settings.JACC. Case reports · 2025Article
- Successful Transcatheter Pulmonary Valve Replacement Via the Azygous Vein in a Patient With Interrupted Inferior Vena Cava.JACC. Case reports · 2025Article
- Early-term results of percutaneous pulmonary valve implantation (valve-in-valve) in dysfunctional bioprosthetic valves in pulmonary position.Turk gogus kalp damar cerrahisi dergisi · 2025Article
- Rupture of a calcified right ventricle to pulmonary artery homograft by balloon dilation- emergency rescue by venus P-Valve.International journal of emergency medicine · 2024Article
- Percutaneous pulmonary valve implantation in a patient with congenitally corrected transposition of the great arteries: a case report.Journal of medical case reports · 2024Article
- Balloon-Expandable Pulmonary Valves for Patched or Native Right Ventricular Outflow Tracts.Pediatric cardiology · 2023Article
- Infective Endocarditis Risk with Melody versus Sapien Valves Following Transcatheter Pulmonary Valve Implantation: A Systematic Review and Meta-Analysis of Prospective Cohort Studies.Journal of clinical medicine · 2023Article
- Percutaneous Transcatheter Closure of Congenital Ventricular Septal Defects.Korean circulation journal · 2023Review
- Staged Percutaneous Management of Pulmonary Atresia and Intact Interventricular Septum: Stretching the Limits.Journal of interventional cardiology · 2023Article
- Coronary Artery Anomalies and Their Impact on the Feasibility of Percutaneous Pulmonary Valve Implantation.Pediatric cardiology · 2022Article
- The role of transcatheter approaches for the treatment of pulmonary homograft dysfunction.Annals of cardiothoracic surgery · 2021Article
- The PULSTA valve in native right ventricular outflow tract: initial experience in 3 Spanish hospitals.REC, interventional cardiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Percutaneous pulmonary valve implantation (PPVI) is recognized as a feasible and low risk alternative to surgery to treat dysfunctional right ventricular outflow tract (RVOT) in usually pluri-operated patients. Evolving technology allowed to develop different kind of prosthesis and to go from an initial treatment exclusively of stenotic conduit to an actual approach extended also to wide native RVOT. The Melody transcatheter pulmonary valve (TPV) and the Edwards Sapien valve are nowadays the most commonly implanted prostheses. However, other devices have been developed to treat large RVOT (i.e., the Venus p-valve, the Medtronic Harmony TPV, the Alterra Adaptive Prestent, and the Pulsta valve). Indications for PPVI are the same as for surgical interventions on pulmonary valve, with limits related to the maximum diameter of the available percutaneous prosthesis. Therefore, an accurate preoperative evaluation is of paramount importance to select patients who could benefit from this procedure. The overall periprocedural mortality incidence is around 1.4%, while freedom from RVOT reintervention ranges from 100% at 4 months to 70% at 70 months, according to the different published studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.